ETNB: 89bio, Inc. Company Projected Revenue

ETNB (89bio Corp) - company brandmark

89bio, Inc. is developing an FGF21 therapy to combat liver fibrosis, implementing software for the automated audit of clinical data. The company's future sales model clearly demonstrates the dynamics of expected demand, where 0.00 indicates the level of this metric. The business relies on an asset-light approach, outsourcing drug production to external contract manufacturing organizations.

Company Projected Revenue: 89bio Pharma (ETNB) for 07/04/2022 - 11/15/2025

Analytical breakdowns and data insights for company 89bio Pharma (ETNB)

- stock quotes and analyst forecast:
- market capitalization information:
Fundamental company analysis:89bio, Inc.
Signature product of 89bio Corp

Investors are evaluating the potential of 89bio, Inc. (ETNB) through the lens of digital platform efficiency and automated screening of metabolic drugs. This indicator aggregates market expectations for future cash flows, reflecting the projected commercialization of developments; by analyzing the organization's future sales revenue, one can determine the degree of optimism currently priced in and compare it with the long-term consensus forecast for the asset's fundamental value.

Main competitors

Projected Sales Volume ASND|Company Projected Revenue MDGL (Madrigal Pharmaceuticals Inc)|Company Projected Revenue corcept.com CORT|Rhythm Corp (RYTM) - Company Expected Sales Volume|AKRO - Company Projected Revenue|MTSR: Company Projected Revenue|MLTX: Projected Sales Volume|CRNX - Company Future Sales|Company Projected Revenue NewAmsterdam Pharma Corp|Soleno Therapeutics Corp (SLNO) - Company Future Sales|Company Projected Revenue amicusrx.com (FOLD)|Company Future Sales Volume Agios Pharmaceuticals AGIO|Company Projected Revenue Structure Therapeutics Inc GPCR|MDXG - Company Future Sales Volume|rezolutebio.com - Projected Sales Volume|Company Expected Sales Volume Lexicon Pharmaceuticals|MBX (MBX Biosciences Inc) - Company Future Sales Volume|ALT - Company Future Sales|AARD (Aardvark Therapeutics Corp) - Projected Sales Volume|Sagimet Biosciences, Inc. (SGMT) - Company Future Sales|Projected Sales Volume BIOA|BMEA - Company Expected Sales Volume|Projected Sales Volume QNCX (Quince Therapeutics, Inc.)|fractyl.com (GUTS) - Company Expected Sales Volume|vTv Therapeutics Inc - Projected Sales Volume|ATPC - Projected Sales Volume|Pluri Inc. (PLUR) - Company Projected Revenue|Company Future Sales Volume Synlogic, Inc.|Company Future Sales Volume LPCN|Company Projected Revenue MTNB|Company Projected Revenue sprucebiosciences.com (SPRB)|Galecto - Company Revenue Forecast|Company Projected Revenue Carmell Corp CTCX|LUMO - Company Future Sales Volume|ONVO - Company Projected Revenue|radiuspharm.com (RDUS) - Company Future Sales Volume